my end of year review of DNDN
INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.
DNDN (market cap $5.04B)
Dendreon is a leading edge biotech based on immunotherapy, therefore it is developing treatments known as vaccines instead of drugs. It's first product is Provenge which is approved for treating prostate cancer. It is not a panacea, and it isn't cheap, but it appears to be better and cheaper than the alternatives. It is apparently much better in terms of side effects; e.g. getting the flu versus going through chemo or radiation. The technique and technology may also be applicable to the other cancers like lung, breast, ovarian, bladder, renal, and colo-rectal. Clinical trials for treating bladder cancer have begun. The company has stated a loose goal of initiating a new trial every year. Provenge is being administered at nearly the capacity of the existing facilities. New facilities should be operating next year, and the expansion into Europe should also begin next year, though that is contingent on European approvals.
I feel that the company and the stock are discounted because of habit and investments in chemo and radiation businesses, and a general misunderstanding of the technology's unique approach.
I would like to HOLD, and possibly BUY more, but I have to SELL to pay bills, unless I generate significant income from my book, art, other business interests, or even a windfall. (A man can hope, eh?)
DISCLOSURE LTBH since 2002 and glad to be indirectly part of a dramatic improvement in the lives of cancer patients from the efforts of the Dendreon team.